1037792-97-4

Basic information

• Product Name: 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1037792-97-4
• Molecular Weight: 466.623
• Mol File: 1037792-97-4.mol

Chemical Properties

• CAS DataBase Reference: 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester(1037792-97-4)
• EPA Substance Registry System: 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester(1037792-97-4)

Safety Data

• Hazardous Substances Data: 1037792-97-4(Hazardous Substances Data)

Upstream product

• 1044136-47-1 4-(4-methanesulfonyloxymethylthiazol-2-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 14763-60-1 4-methanesulfonyl-phenol 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 530115-96-9 4-cyano-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 343788-67-0 4-carbamoyl-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 951745-01-0 4-methyl-4-thiocarbamoylpiperidine-1-carboxylic acid tert-butyl ester 
• 955399-88-9 4-(4-ethoxycarbonylthiazol-2-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 1044136-46-0 4-(4-hydroxymethylthiazol-2-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS

Use of oxymethylene aryl GPRl 19 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provide

HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.